Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A single-arm, open-label clinical trial to assess the effects and safety of anlotinib
hydrochloride combined with transcatheter arterial chemoembolization (TACE) in hepatocellular
carcinoma(HCC) patients at high risk of post surgery recurrence.
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University